Business

Announcement on Voluntary Disclosure of Inclusion of Furmonertinib Mesylate Tablets for EGFR PACC-mutant NSCLC First-line Treatment in the Proposed Breakthrough Therapy Designation

Announcement on Voluntary Disclosure of Inclusion of Furmonertinib Mesylate Tablets for EGFR PACC-mutant NSCLC First-line Treatment in the Proposed Breakthrough Therapy Designation

articleShanghai Allist Pharmaceuticals Co. Ltd. Class ADecember 25, 20255/news/announcement-on-voluntary-disclosure-of-inclusion-of-furmonertinib-mesylate-tablets-for-egfr-pacc-mutant-nsclc-first-line-treatment-in-the-proposed-breakthrough-therapy-designation
Announcement on Voluntary Disclosure of Inclusion of Furmonertinib Mesylate Tablets for EGFR PACC-mutant NSCLC First-line Treatment in the Proposed Breakthrough Therapy Designation

About this update from Shanghai Allist Pharmaceuticals Co. Ltd. Class A

Announcement on Voluntary Disclosure of Inclusion of Furmonertinib Mesylate Tablets for EGFR PACC-mutant NSCLC First-line Treatment in the Proposed Breakthrough Therapy Designation The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Shanghai Allist Pharmaceuticals Co. Ltd. Class A